Prostate cancer (PCa) is the most prevalent cancer among men in the United States and
remains the second-leading cause of cancer mortality in men. Paclitaxel (PTX) is the first line …

Prostate cancer (PC) is the second most commonly occurring cancer in men. Conventional
chemotherapy has wide variety of disadvantages such as high systemic toxicity and low …

Prostate cancer is primarily fatal after it becomes metastatic and castration-resistant despite
novel combined hormonal and chemotherapeutic regimens. Hence, new therapeutic …

Prostate-specific membrane antigen (PSMA) provides an attractive target for the
development of targeted chemotherapeutics for prostate cancer. We have designed and …

Prostate cancer (PCa) is a major cause of mortality and morbidity in Western society today.
Current methods for detecting PCa are limited, leaving most early malignancies …

We developed a model small-molecule drug conjugate (SMDC) that employed doxorubicin
as a representative chemotherapeutic targeted to the cell membrane biomarker PSMA …

Combination of targeted delivery and controlled release is a powerful technique for cancer
treatment. In this paper, we describe the design, synthesis, structure validation and …

Active targeting to cancer involves exploiting specific interactions between receptors on the
surface of cancer cells and targeting moieties conjugated to the surface of vectors such that …

Most patients with advanced prostate cancer (PCa) will develop metastatic castration-
resistant prostate cancer (mCRPC) after androgen deprivation therapy, at this time the tumor …

Simple Summary Currently, there is no effective treatment that can cure metastatic prostate
cancer. Various pros-tate specific membrane antigen (PSMA)-targeted radioimaging and …